$Sharps Technology (STSS.US)$ $Verb Technology (VERB.US)$ $High Roller Technologies (ROLR.US)$ $Iveda Solutions (IVDA.US)$ $Cingulate (CING.US)$ $Star Equity (STRR.US)$ $Jowell Global (JWEL.US)$ $Cyclerion Therapeutics (CYCN.US)$ $Digital Ally (DGLY.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Silexion Therapeutics (SLXN.US)$ $Exicure (XCUR.US)$ $Forte Biosciences (FBRX.US)$
📊⚡️📊

$Revelation Biosciences (REVB.US)$ $Nukkleus (NUKK.US)$ $Lm Funding America (LMFA.US)$ $Sonoma Pharmaceuticals (SNOA.US)$ $Vertical Aerospace (EVTL.US)$ $Advent Technologies (ADN.US)$ $Avalon Holdings (AWX.US)$ $LakeShore Biopharma (LSB.US)$ $Vicarious Surgical (RBOT.US)$ $Protagenic Therapeutics (PTIX.US)$ $Cingulate (CING.US)$ $BTC Digital (BTCT.US)$ $SemiLEDs (LEDS.US)$ $SU Group Holdings (SUGP.US)$
📊⚡️📊

$Cingulate (CING.US)$ i will keep my eyes on this one

$Cingulate (CING.US)$
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Positive
Working capital increased by $19.5M from December 2023
Raised $12.5M in capital during Q3 2024
Net loss decreased by 46% YoY to $3.2M
R&D expenses reduced by $2.5M YoY
Secured European patents for CTx-1301 in up to 30 territories
Regained Nasdaq compliance with $1.00 minimum bid requirement
Negative
Accumulated deficit increa...

$Cingulate (CING.US)$ drop down again